Neoplasms by Histologic Type  >>  delanzomib (CEP-18770)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
delanzomib (CEP-18770) / Teva
NCT00572637: Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas

Completed
1
55
Europe
CEP-18770
Ethical Oncology Science
Solid Tumors, Lymphoma, Non-Hodgkin
03/10
03/10

Download Options